α4β7 x IL-23
VIAL-α4β7xIL23-HLE is a half-life extended bi-specific antibody, powered by VIAL-HLE proprietary half-life extension technology, to increase time of exposure to enable more durable response. This targets both immune cell migration and inflammation to provide a best-in-class therapy for patients with IBD.
- Development candidates to be selected by Q3 2025.
- Novel combination of known targets to break the IBD efficacy ceiling.
- Extended half-life for sustained exposure and less frequent dosing to improve patient convenience.
Key Data
Based on in vitro and in vivo studies, VIAL-INHBE effectively demonstrates functional potency and target-binding comparable to or better than clinical programs.
Genetically validated target
- TMPRSS6 loss of function is genetically validated to improve iron homeostasis.
- Reduced TMPRSS6 activity raises hepcidin, improving iron balance and protecting against overload.
- Loss-of-function variants in the TMPRSS6 gene are associated with low hemoglobin and iron deficiency anemia.
Key data highlights
- VIAL-TMPRSS6 is progressing to demonstrate an equal-or-better profile across potency, dosing frequency, and safety compared to other assets in development for PV.
- VIAL-TMPRSS6 demonstrated superior stability in NHP liver lysates (S9 fractions) suggesting improved knockdown durability and the potential for less frequent dosing.
